Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H2 2019’, provides an overview of the Keratoconjunctivitis sicca (Dry Eye) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye)

– The report reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Keratoconjunctivitis sicca (Dry Eye) therapeutics and enlists all their major and minor projects

– The report assesses Keratoconjunctivitis sicca (Dry Eye) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye)”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“AB2 Bio Ltd

Abilita Bio Inc

Actinobac Biomed Inc

Aerie Pharmaceuticals Inc

Aldeyra Therapeutics Inc

Allegro Ophthalmics LLC

Allergan Plc

Allosterix Ltd

Allysta Pharmaceuticals Inc

Apidel SA

Ascendia Pharmaceuticals LLC

Aurinia Pharmaceuticals Inc

Aviara Pharmaceuticals Inc

Avizorex Pharma SL

AxeroVision Inc

Azura Ophthalmics Ltd

Bessor Pharma LLC

BRIM Biotechnology Inc

Cambium Medical Technologies LLC

Cellix Bio Pvt Ltd

Dhp Korea Ltd

Dompe Farmaceutici SpA

Emerald Bioscience Inc

EyGen Ltd

Feldan Therapeutics Inc

GL Pharm Tech Corp

Glaukos Corp

Glia LLC

HanAll Biopharma Co Ltd

Huons Co Ltd

Huons Global Co Ltd

Icure Pharmaceutical Inc

Ipsen SA

IVIEW Therapeutics Inc

Kala Pharmaceuticals Inc

Kowa Co Ltd

Kukje Pharmaceutical Industry Co Ltd

Kv1.3 Therapeutics

Laboratoires Thea SA

Laboratorios Sophia SA de CV

Lee’s Pharmaceutical Holdings Ltd

LTT Bio-Pharma Co Ltd

Lubris Biopharma

Marinomed Biotech AG

MC2 Therapeutics AS

Merck & Co Inc

Mitotech SA

MyX Therapeutics Inc

Nanomerics Ltd

Neuroptika Inc

Novaliq GmbH

Novartis AG

Noveome Biotherapeutics Inc

OccuRx Pty Ltd

Ocugen Inc

Ocular Therapeutix Inc

Oculis SA

Ocunova LLC

OKYO Pharma Ltd

OncoNOx ApS

Oyster Point Pharma Inc

Palatin Technologies Inc

Panag Pharma Inc

Panoptes Pharma GesmbH

Pharmaleads SA

Pleryon Therapeutics Ltd

Proteris Biotech Inc

Quorum Innovations LLC

Redwood Pharma AB

RegeneRx Biopharmaceuticals Inc

RHNanopharmacuticals LLC

RiniSight Inc

Samjin Pharm Co Ltd

Santen Pharmaceutical Co Ltd

Senju Pharmaceutical Co Ltd

Serentrix LLC

Silk Technologies Ltd

Stuart Therapeutics Inc

Surface Pharmaceuticals Inc

Sylentis SAU

Tarsius Pharma Ltd

TearSolutions LLC

Tetra Bio-Pharma Inc

TopiVert Ltd

Vanda Pharmaceuticals Inc

Xigen SA

Yuyu Pharma Inc”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Keratoconjunctivitis Sicca (Dry Eye) Overview 6

Keratoconjunctivitis Sicca (Dry Eye) Therapeutics Development 7

Keratoconjunctivitis Sicca (Dry Eye) Therapeutics Assessment 20

Keratoconjunctivitis Sicca (Dry Eye) Companies Involved in Therapeutics Development 30

Keratoconjunctivitis Sicca (Dry Eye) Drug Profiles 48

Keratoconjunctivitis Sicca (Dry Eye) Dormant Projects 205

Keratoconjunctivitis Sicca (Dry Eye) Discontinued Products 209

Keratoconjunctivitis Sicca (Dry Eye) Product Development Milestones 210

Appendix 218

List of Tables

“List of Tables

Table 1: Number of Products under Development for Keratoconjunctivitis Sicca (Dry Eye), H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Table 7: Number of Products under Development by Universities/Institutes, H2 2019

Table 8: Products under Development by Companies, H2 2019

Table 9: Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 10: Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 11: Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 12: Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Table 13: Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Table 14: Products under Development by Universities/Institutes, H2 2019

Table 15: Number of Products by Stage and Target, H2 2019

Table 16: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Table 17: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Table 18: Number of Products by Stage and Mechanism of Action, H2 2019

Table 19: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Table 20: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Table 21: Number of Products by Stage and Route of Administration, H2 2019

Table 22: Number of Products by Stage and Molecule Type, H2 2019

Table 23: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by AB2 Bio Ltd, H2 2019

Table 24: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Abilita Bio Inc, H2 2019

Table 25: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Actinobac Biomed Inc, H2 2019

Table 26: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Aerie Pharmaceuticals Inc, H2 2019

Table 27: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Aldeyra Therapeutics Inc, H2 2019

Table 28: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Allegro Ophthalmics LLC, H2 2019

Table 29: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Allergan Plc, H2 2019

Table 30: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Allosterix Ltd, H2 2019

Table 31: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Allysta Pharmaceuticals Inc, H2 2019

Table 32: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Apidel SA, H2 2019

Table 33: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Ascendia Pharmaceuticals LLC, H2 2019

Table 34: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Aurinia Pharmaceuticals Inc, H2 2019

Table 35: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Aviara Pharmaceuticals Inc, H2 2019

Table 36: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Avizorex Pharma SL, H2 2019

Table 37: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by AxeroVision Inc, H2 2019

Table 38: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Azura Ophthalmics Ltd, H2 2019

Table 39: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Bessor Pharma LLC, H2 2019

Table 40: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by BRIM Biotechnology Inc, H2 2019

Table 41: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Cambium Medical Technologies LLC, H2 2019

Table 42: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Cellix Bio Pvt Ltd, H2 2019

Table 43: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Dhp Korea Ltd, H2 2019

Table 44: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Dompe Farmaceutici SpA, H2 2019

Table 45: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Emerald Bioscience Inc, H2 2019

Table 46: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by EyGen Ltd, H2 2019

Table 47: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Feldan Therapeutics Inc, H2 2019

Table 48: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by GL Pharm Tech Corp, H2 2019

Table 49: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Glaukos Corp, H2 2019

Table 50: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Glia LLC, H2 2019

Table 51: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by HanAll Biopharma Co Ltd, H2 2019

Table 52: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Huons Co Ltd, H2 2019

Table 53: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Huons Global Co Ltd, H2 2019

Table 54: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Icure Pharmaceutical Inc, H2 2019

Table 55: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Ipsen SA, H2 2019

Table 56: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by IVIEW Therapeutics Inc, H2 2019

Table 57: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Kala Pharmaceuticals Inc, H2 2019

Table 58: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Kowa Co Ltd, H2 2019

Table 59: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2019

Table 60: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Kv1.3 Therapeutics, H2 2019”

List of Figures

“List of Figures

Figure 1: Number of Products under Development for Keratoconjunctivitis Sicca (Dry Eye), H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products under Development by Universities/Institutes, H2 2019

Figure 4: Number of Products by Top 10 Targets, H2 2019

Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019

Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Figure 8: Number of Products by Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Routes of Administration, H2 2019

Figure 10: Number of Products by Molecule Types, H2 2019

Figure 11: Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports